Israeli - Kiebrania - Ministry of Health

pfizer pharmaceuticals israel ltd - azithromycin - אבקה להכנת תרחיף - azithromycin 2.096 g - azithromycin - azithromycin - zmax is indicated for the treatment of patients 18 years of age and above with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. adults: acute bacterial sinusitis due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniae. community-acquired pneumonia due to chlamydophila pneumoniae, haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy.

Israeli - Kiebrania - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - תמיסה לאינפוזיה - moxifloxacin as hydrochloride 1.6 mg/ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.

Israeli - Kiebrania - Ministry of Health

bayer israel ltd - moxifloxacin - תמיסה לאינפוזיה - moxifloxacin 400 mg / 250 ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.

Israeli - Kiebrania - Ministry of Health

gilead sciences israel ltd - amphotericin b - אבקה להכנת תרכיז לאינפוזיה - amphotericin b 50 mg/vial - amphotericin b - amphotericin b - antifungal antibiotic for the treatment of severe systemic and/or deep mycoses where toxicity precludes the use of conventional systemic amphotericin b in effective dosages. this drug should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests. ambisome is also indicated for the treatment of systemic fungal infections in immunocompromised patients (e.g. patients with aids or cancer). ambisome is also indicated for the primary therapy of visceral leishmaniasis in immunocompetent patients and immunocompromised patients (e.g. hiv positive). empirical treatment of presumed fungal infection in febrile neutropenic patients.

Israeli - Kiebrania - Ministry of Health

j-c health care ltd - itraconazole 100 mg - capsules - itraconazole - blastomycosis (pulmonary and extrapulmonary). histoplasmosis . onychomycosis caused by dermatophytes and/or yeasts. dermatomycoses. vulvovaginal candidosis. oral candidosis. prevention of fungal infection during neutropenia in immunodeficient patients.

Israeli - Kiebrania - Ministry of Health

rafa laboratories ltd - itraconazole - קפסולות - itraconazole 100 mg - itraconazole - itraconazole - blastomycosis (pulmonary and extrapulmonary). histoplasmosis. onchomycosis caused by dermatophytes and/or yeast. dermatomycoses. vulvovaginal candidosis. oral candidosis. prevention of fungal infection during neutropenia in immunodeficient patients.

Israeli - Kiebrania - Ministry of Health

megapharm ltd - cyclophosphamide - אבקה להכנת תמיסה לזריקה - cyclophosphamide 500 mg/vial - cyclophosphamide - cyclophosphamide - malignant diseases: cycophosphamide although effective alone in susceptible melignancies is more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible. cycophosphamide treatment: 1) malignant lymphomas (stages iii and iv of the ann arbor staging system) hodgkin`s disease lymphocytic lymphoma (nodular or diffuse) mixed-cell type lymphoma histiocytic lymphoma burkitt`s lymphoma. 2) multiple myeloma. 3) leukemias: chronic lymphocytic leukemia chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis) acute myelogenous and monocytic leukemia acute lymphoblastic (stemcell) leukemia in children. 4) mycosis fungoides (advenced disease). 5) neuroblastoma (disseminated disease). 6) adenocarcinoma of the ovary. 7) retinoblastoma. 8) carcinoma of the breast. nonmallgnant disease biopsy proven "minimal change" nephrotic syndrome in children whose disease fails to respond adequately to another treatment. severe cases of systemi

Israeli - Kiebrania - Ministry of Health

megapharm ltd - cyclophosphamide - אבקה להכנת תמיסה לזריקה - cyclophosphamide 1 g/vial - cyclophosphamide - cyclophosphamide - malignant diseases: cycophosphamide although effective alone in susceptible melignancies is more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible. cycophosphamide treatment: 1) malignant lymphomas (stages iii and iv of the ann arbor staging system) hodgkin`s disease lymphocytic lymphoma (nodular or diffuse) mixed-cell type lymphoma histiocytic lymphoma burkitt`s lymphoma. 2) multiple myeloma. 3) leukemias: chronic lymphocytic leukemia chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis) acute myelogenous and monocytic leukemia acute lymphoblastic (stemcell) leukemia in children. 4) mycosis fungoides (advenced disease). 5) neuroblastoma (disseminated disease). 6) adenocarcinoma of the ovary. 7) retinoblastoma. 8) carcinoma of the breast. nonmallgnant disease biopsy proven "minimal change" nephrotic syndrome in children whose disease fails to respond adequately to another treatment. severe cases of systemi

Israeli - Kiebrania - Ministry of Health

abic marketing ltd, israel - methotrexate - תמיסה להזרקה - methotrexate 25 mg/ml - methotrexate - methotrexate - antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. palliation of acute lymphocytic leukemia. abitrexate is also indicated in the treatment and prophylaxis of meningeal leukemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. in combination with other anticancer agents, abitrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. abitrexate is effective in the treatment of the advanced stages (iii and iv peter's staging system) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. psoriasis: because of the high risk attending its use, abitrexate is

Israeli - Kiebrania - Ministry of Health

pharmalogic ltd - methotrexate 10 mg/ml - solution for injection - methotrexate - antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. palliation of acute lymphocytic leukemia. in the treatment and prophylaxis of meningeal leukemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. in combination with other anticancer agents, methotrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. methotrexate is effective in the treatment of the advanced stages (iii and iv peter's staging system) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. psoriasis: because of the high risk attending its use, methotrexate is indicated only in the